WallStreetZenWallStreetZen

NASDAQ: BVS
Bioventus Inc Stock

Open Broker Account
$2.25+0.12 (+5.63%)
Updated Dec 5, 2022
BVS Price
$2.25
Fair Value Price
$2.80
Market Cap
$174.91M
52 Week Low
$1.65
52 Week High
$15.57
P/E
-1.09x
P/B
0.51x
P/S
0.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$516.70M
Earnings
-$127.14M
Gross Margin
66.7%
Operating Margin
-31.67%
Profit Margin
-24.6%
Debt to Equity
2.97
Operating Cash Flow
-$6M
Beta
1.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BVS Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Zen Score

Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BVS ($2.25) is undervalued by 19.72% relative to our estimate of its Fair Value price of $2.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BVS ($2.25) is not significantly undervalued (19.72%) relative to our estimate of its Fair Value price of $2.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BVS due diligence checks available for Premium users.

Be the first to know about important BVS news, forecast changes, insider trades & much more!

BVS News

Valuation

BVS fair value

Fair Value of BVS stock based on Discounted Cash Flow (DCF)
Price
$2.25
Fair Value
$2.80
Undervalued by
19.72%
BVS ($2.25) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BVS ($2.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BVS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.09x
Industry
35.84x
Market
21.63x

BVS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
4.38x
BVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BVS's financial health

Profit margin

Revenue
$128.7M
Net Income
-$108.2M
Profit Margin
-84.1%
BVS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BVS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.4B
Liabilities
$1.0B
Debt to equity
2.97
BVS's short-term liabilities ($288.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BVS's long-term liabilities ($730.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$701.0k
Investing
-$56.3M
Financing
$50.7M
BVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BVS vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
BVS$174.91M+5.63%-1.09x0.51x
STIM$168.77M+0.16%-4.56x2.68x
ANIX$153.00M+2.04%-10.62x4.83x
PRE$203.09M+1.10%-0.13x0.98x
NOTV$144.35M-6.16%N/A0.24x

Bioventus Stock FAQ

What is Bioventus's quote symbol?

NASDAQ: BVS) Bioventus trades on the NASDAQ under the ticker symbol BVS. Bioventus stock quotes can also be displayed as NASDAQ: BVS.

If you're new to stock investing, here's how to buy Bioventus stock.

What is the 52 week high and low for Bioventus (NASDAQ: BVS)?

(NASDAQ: BVS) Bioventus's 52-week high was $15.57, and its 52-week low was $1.65. It is currently -85.55% from its 52-week high and 36.36% from its 52-week low.

How much is Bioventus stock worth today?

(NASDAQ: BVS) Bioventus currently has 77,738,595 outstanding shares. With Bioventus stock trading at $2.25 per share, the total value of Bioventus stock (market capitalization) is $174.91M.

Bioventus stock was originally listed at a price of $19.21 in Feb 11, 2021. If you had invested in Bioventus stock at $19.21, your return over the last 1 years would have been -88.29%, for an annualized return of -88.29% (not including any dividends or dividend reinvestments).

How much is Bioventus's stock price per share?

(NASDAQ: BVS) Bioventus stock price per share is $2.25 today (as of Dec 5, 2022).

What is Bioventus's Market Cap?

(NASDAQ: BVS) Bioventus's market cap is $174.91M, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioventus's market cap is calculated by multiplying BVS's current stock price of $2.25 by BVS's total outstanding shares of 77,738,595.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.